Trilantic, a private equity firm, agreed to invest in SOFIE Biosciences, a radiopharmacy and contract development and manufacturing organization. Financial terms were not disclosed. The investment is being made in partnership with SOFIE’s founding team, who will retain a meaningful equity stake and continue to lead the business.